Key facts
- It has raised $31.7M; the latest was Seed Round ($31.4M) in Mar 2025.
- Notable investors include Cambridge Enterprise Ventures, M Ventures, SV Health Investors, Pfizer Ventures, Cambridge Innovation Capital — 10 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for TRIMTECH Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for TRIMTECH Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About TRIMTECH Therapeutics
Developer of a targeted protein degradation platform designed to address neurodegenerative diseases by degrading toxic protein aggregates. The company's platform offers oral therapeutics with specificity for aggregated proteins, a safety profile, and the potential for personalized treatment approaches for neurological, inflammatory, and oncological conditions, enabling patients to access effective and safe therapies.
- Sector
- Healthcare
- HQ
- Cambridge, United Kingdom
- Founded
- 2023
- Employees
- 4
- Website
- trimtechtherapeutics.com/
- Ownership
- Privately Held (backing)
TRIMTECH Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in TRIMTECH Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on TRIMTECH Therapeutics in its N-PORT filings yet. We sweep new filings monthly.